利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.042 秒)

    Spirochromanone carboxylic acids
    1.
    发明授权
    Spirochromanone carboxylic acids 有权
    新型螺环酮羧酸

    公开(公告)号：US08524730B2

    公开(公告)日：2013-09-03

    申请号：US12997263

    申请日：2009-06-29

    申请人： Hideki Jona ,  Yoshihiro Shibata ,  Takeru Yamakawa

    发明人： Hideki Jona ,  Yoshihiro Shibata ,  Takeru Yamakawa

    IPC分类号： C07D405/04 ,  A61K31/438

    CPC分类号： C07D491/107 ,  A61K31/438 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709

    摘要： The invention relates to a compound of a general formula (I): wherein A represents a linking group; Ar1 represents a group formed from an aromatic ring; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkoxy group, a cyclo-C3-C6 alkyloxy group, a C2-C7 alkanoyl group, a halo-C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, a halo-C2-C7 alkoxycarbonyl group, a cyclo-C3-C6 alkyloxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; a C1-C6 alkyl group optionally having substituent(s); an aryl or heterocyclic group optionally having substituent(s); or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nitrogen atom or a methine group; and V represents an oxygen atom, a sulfur atom or an imino group. The compound of the invention is useful as therapeutical agents for various ACC-related diseases.

    摘要翻译： 本发明涉及通式（I）的化合物：其中A表示连接基团; Ar 1表示由芳香环形成的基团; R 1和R 2各自独立地表示氢原子，卤素原子，氰基，C 2 -C 6烯基，C 1 -C 6烷氧基，卤代-C 1 -C 6烷氧基，环-C 3 -C 6烷氧基， C2-C7烷酰基，卤代-C2-C7烷酰基，C2-C7烷氧基羰基，卤代-C2-C7烷氧基羰基，环-C3-C6烷氧基羰基，芳烷氧基羰基，氨基甲酰基C1- C6烷氧基，羧基-C2-C6烯基或-Q1-N（Ra）-Q2-Rb的基团; 任选具有取代基的C1-C6烷基; 任选具有取代基的芳基或杂环基; 或具有芳基或杂环基的C 1 -C 6烷基或C 2 -C 6烯基; T和U各自独立地表示氮原子或次甲基; V表示氧原子，硫原子或亚氨基。 本发明的化合物可用作各种ACC相关疾病的治疗剂。

    NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS
    2.
    发明申请
    NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS 有权
    新型螺环酮羧酸

    公开(公告)号：US20110077262A1

    公开(公告)日：2011-03-31

    申请号：US12997263

    申请日：2009-06-29

    申请人： Hideki Jona ,  Yoshihiro Shibata ,  Takeru Yamakawa

    发明人： Hideki Jona ,  Yoshihiro Shibata ,  Takeru Yamakawa

    IPC分类号： A61K31/438 ,  C07D491/107 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  A61P31/00

    CPC分类号： C07D491/107 ,  A61K31/438 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709

    摘要： The invention relates to a compound of a general formula (I): wherein A represents a linking group; Ar1 represents a group formed from an aromatic ring; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkoxy group, a cyclo-C3-C6 alkyloxy group, a C2-C7 alkanoyl group, a halo-C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, a halo-C2-C7 alkoxycarbonyl group, a cyclo-C3-C6 alkyloxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; a C1-C6 alkyl group optionally having substituent(s); an aryl or heterocyclic group optionally having substituent(s); or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nitrogen atom or a methine group; and V represents an oxygen atom, a sulfur atom or an imino group. The compound of the invention is useful as therapeutical agents for various ACC-related diseases.

    摘要翻译： 本发明涉及通式（I）的化合物：其中A表示连接基团; Ar 1表示由芳香环形成的基团; R 1和R 2各自独立地表示氢原子，卤素原子，氰基，C 2 -C 6烯基，C 1 -C 6烷氧基，卤代-C 1 -C 6烷氧基，环-C 3 -C 6烷氧基， C2-C7烷酰基，卤代-C2-C7烷酰基，C2-C7烷氧基羰基，卤代-C2-C7烷氧基羰基，环-C3-C6烷氧基羰基，芳烷氧基羰基，氨基甲酰基C1- C6烷氧基，羧基-C2-C6烯基或-Q1-N（Ra）-Q2-Rb的基团; 任选具有取代基的C1-C6烷基; 任选具有取代基的芳基或杂环基; 或具有芳基或杂环基的C 1 -C 6烷基或C 2 -C 6烯基; T和U各自独立地表示氮原子或次甲基; V表示氧原子，硫原子或亚氨基。 本发明的化合物可用作各种ACC相关疾病的治疗剂。

    Spirochromanon derivatives
    3.
    发明授权
    Spirochromanon derivatives 有权
    螺二色素衍生物

    公开(公告)号：US08138197B2

    公开(公告)日：2012-03-20

    申请号：US12518466

    申请日：2008-01-08

    申请人： Tomoharu Iino ,  Hideki Jona ,  Hideki Kurihara ,  Masayuki Nakamura ,  Kenji Niiyama ,  Jun Shibata ,  Tadashi Shimamura ,  Hitomi Watanabe ,  Takeru Yamakawa ,  Lihu Yang

    发明人： Tomoharu Iino ,  Hideki Jona ,  Hideki Kurihara ,  Masayuki Nakamura ,  Kenji Niiyama ,  Jun Shibata ,  Tadashi Shimamura ,  Hitomi Watanabe ,  Takeru Yamakawa ,  Lihu Yang

    IPC分类号： A61K31/438 ,  C07D221/20

    CPC分类号： C07D491/107 ,  C07D491/20 ,  C07D519/00

    摘要： The invention relates to a compound of a general formula (I): wherein Ar1 represents a group formed from an aromatic ring selected from a group consisting of benzene, pyrazole, isoxazole, pyridine, indole, 1H-indazole, 1H-furo[2,3-c]pyrazole, 1H-thieno[2,3-c]pyrazole, benzimidazole, 1,2-benzisoxazole, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine and 1H-pyrazolo[3,4-a]pyridine, having Ar2, and optionally having one or two or more substituents selected from R3; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; or a C1-C6 alkyl group optionally having a substituent; or an aryl or heterocyclic group optionally having a substituent; or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nitrogen atom or a methine group; and V represents an oxygen atom or a sulfur atom. The compound of the invention is useful as therapeutical agents for various ACC-related diseases.

    摘要翻译： 本发明涉及通式（I）的化合物：其中Ar 1表示由选自苯，吡唑，异恶唑，吡啶，吲哚，1H-吲唑，1H-呋喃并[ 3-c]吡唑，1H-噻吩并[2,3-c]吡唑，苯并咪唑，1,2-苯并异恶唑，咪唑并[1,2-a]吡啶，咪唑并[1,5-a]吡啶和1H-吡唑并[ 3,4-a]吡啶，其具有Ar 2，并且任选具有一个或两个或更多个选自R 3的取代基; R 1和R 2各自独立地表示氢原子，卤素原子，氰基，C 2 -C 6烯基，C 1 -C 6烷氧基，C 2 -C 7烷酰基，C 2 -C 7烷氧基羰基，芳烷氧基羰基， 氨基甲酰基-C 1 -C 6烷氧基，羧基-C 2 -C 6烯基或-Q 1 -N（R a）-Q 2 -R b的基团; 或任选具有取代基的C1-C6烷基; 或任选具有取代基的芳基或杂环基; 或具有芳基或杂环基的C 1 -C 6烷基或C 2 -C 6烯基; T和U各自独立地表示氮原子或次甲基; V表示氧原子或硫原子。 本发明的化合物可用作各种ACC相关疾病的治疗剂。

    Substituted spirochromanone derivatives
    4.
    发明授权
    Substituted spirochromanone derivatives 有权
    取代的螺二氢茚酮衍生物

    公开(公告)号：US08093389B2

    公开(公告)日：2012-01-10

    申请号：US12007000

    申请日：2008-01-08

    申请人： Tomoharu Iino ,  Hideki Jona ,  Jun Shibata ,  Tadashi Shimamura ,  Takeru Yamakawa ,  Lihu Yang

    发明人： Tomoharu Iino ,  Hideki Jona ,  Jun Shibata ,  Tadashi Shimamura ,  Takeru Yamakawa ,  Lihu Yang

    IPC分类号： C07D413/06 ,  C07D405/04 ,  A61K31/438

    CPC分类号： C07D519/00 ,  C07D491/10

    摘要： The invention relates to a compound of a general formula (I): wherein Ar1 represents a group formed from an aromatic ring selected from a group consisting of indole, 1H-indazole, 2H-indazole, 1H-thieno[2,3-c]pyrazole, 1H-pyrazolo[3,4-b]pyridine, benzo[b]furan, benzimidazole, benzoxazole, 1,2-benzisoxazole and imidazo[1,2-a]pyridine; R1 and R2 each represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkoxy group, a cyclo-C3-C6 alkyloxy group, a C2-C7 alkanoyl group, a halo-C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, a halo-C2-C7 alkoxycarbonyl group, a cyclo-C3-C6 alkyloxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; an optionally-substituted C1-C6 alkyl, aryl or heterocyclic group; or a C1-C6 alkyl or C2-C6 alkenyl group having the aryl or heterocyclic group; R3 and R4 each represent a hydrogen atom, a halogen atom, a nitro group, a cyclo-C3-C6 alkyl group, a carbamoyl group optionally substituted with a C1-C6 alkyl or cyclo-C3-C6 alkyl group, or a group of —N(Re)Rf; an optionally-substituted C2-C7 alkanoyl, C1-C6 alkoxy, C2-C7 alkoxycarbonyl, cyclo-C3-C6 alkyloxycarbonyl, C1-C6 alkylsulfonyl, C1-C6 alkylthio, cyclo-C3-C6 alkyloxy, cyclo-C3-C6 alkyl-C1-C6 alkoxy, cyclo-C3-C6 alkylsulfonyl, cyclo-C3-C6 alkylthio or cyclo-C3-C6 alkyl-C1-C6 alkylthio group; or an optionally-substituted C1-C6 alkyl group; T and U each represent a nitrogen atom or a methine group; and V represents an oxygen atom or a sulfur atom. The compound of the invention is useful as therapeutical agents for various ACC-related diseases.

    摘要翻译： 本发明涉及通式（I）的化合物：其中Ar1表示由选自吲哚，1H-吲唑，2H-吲唑，1H-噻吩并[2,3-c]所示的芳环形成的基团， 吡唑，1H-吡唑并[3,4-b]吡啶，苯并[b]呋喃，苯并咪唑，苯并恶唑，1,2-苯并异恶唑和咪唑并[1,2-a] R 1和R 2各自表示氢原子，卤素原子，氰基，C 2 -C 6烯基，C 1 -C 6烷氧基，卤代-C 1 -C 6烷氧基，环-C 3 -C 6烷氧基， C2-C7烷酰基，卤代-C2-C7烷酰基，C2-C7烷氧基羰基，卤代-C2-C7烷氧基羰基，环-C3-C6烷氧基羰基，芳烷氧基羰基，氨基甲酰基-C1-C6 烷氧基，羧基-C2-C6烯基或-Q1-N（Ra）-Q2-Rb的基团; 任选取代的C 1 -C 6烷基，芳基或杂环基; 或具有芳基或杂环基的C 1 -C 6烷基或C 2 -C 6烯基; R 3和R 4各自表示氢原子，卤素原子，硝基，环-C 3 -C 6烷基，任选被C 1 -C 6烷基或环-C 3 -C 6烷基取代的氨基甲酰基，或者 -N（R f）R f; 任选取代的C 2 -C 7烷酰基，C 1 -C 6烷氧基，C 2 -C 7烷氧基羰基，环C 3 -C 6烷氧基羰基，C 1 -C 6烷基磺酰基，C 1 -C 6烷硫基，环C 3 -C 6烷氧基，环C 3 -C 6烷基 - C 1 -C 6烷氧基，环-C 3 -C 6烷基磺酰基，环-C 3 -C 6烷硫基或环-C 3 -C 6烷基-C 1 -C 6烷硫基; 或任选取代的C 1 -C 6烷基; T和U各自表示氮原子或次甲基; V表示氧原子或硫原子。 本发明的化合物可用作各种ACC相关疾病的治疗剂。

    SPIROCHROMANON DERIVATIVES
    8.
    发明申请
    SPIROCHROMANON DERIVATIVES 有权
    螺吡喃衍生物

    公开(公告)号：US20090270436A1

    公开(公告)日：2009-10-29

    申请号：US12518466

    申请日：2008-01-08

    申请人： Tomoharu Iino ,  Hideki Jona ,  Hideki Kurihara ,  Masayuki Nakamura ,  Kenji Niiyama ,  Jun Shibata ,  Tadashi Shimamura ,  Hitomi Watanabe ,  Takeru Yamakawa ,  Lihu Yang

    发明人： Tomoharu Iino ,  Hideki Jona ,  Hideki Kurihara ,  Masayuki Nakamura ,  Kenji Niiyama ,  Jun Shibata ,  Tadashi Shimamura ,  Hitomi Watanabe ,  Takeru Yamakawa ,  Lihu Yang

    IPC分类号： A61K31/438 ,  C07D401/14 ,  A61P3/00 ,  A61P35/00 ,  A61P31/00

    CPC分类号： C07D491/107 ,  C07D491/20 ,  C07D519/00

    摘要： The invention relates to a compound of a general formula (I): wherein Ar1 represents a group formed from an aromatic ring selected from a group consisting of benzene, pyrazole, isoxazole, pyridine, indole, 1H-indazole, 1H-furo[2,3-c]pyrazole, 1H-thieno[2,3-c]pyrazole, benzimidazole, 1,2-benzisoxazole, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine and 1H-pyrazolo[3,4-b]pyridine, having Ar2, and optionally having one or two or more substituents selected from R3: R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; or a C1-C6 alkyl group optionally having a substituent; or an aryl or heterocyclic group optionally having a substituent; or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nitrogen atom or a machine group; and V represents an oxygen atom or a sulfur atom. The compound of the invention is useful as therapeutical agents for various ACC-related diseases.

    摘要翻译： 本发明涉及通式（I）的化合物：其中Ar 1表示由选自苯，吡唑，异恶唑，吡啶，吲哚，1H-吲唑，1H-呋喃并[ 3-c]吡唑，1H-噻吩并[2,3-c]吡唑，苯并咪唑，1,2-苯并异恶唑，咪唑并[1,2-a]吡啶，咪唑并[1,5-a]吡啶和1H-吡唑并[ 具有Ar 2且任选具有一个或两个以上选自R 3：R 1和R 2的取代基的3,4-b]吡啶各自独立地表示氢原子，卤素原子，氰基，C 2 -C 6烯基， C1-C6烷氧基，C2-C7烷酰基，C2-C7烷氧基羰基，芳烷氧基羰基，氨基甲酰基C1-C6烷氧基，羧基-C2-C6链烯基或-Q1-N （Ra）-Q2-Rb; 或任选具有取代基的C1-C6烷基; 或任选具有取代基的芳基或杂环基; 或具有芳基或杂环基的C 1 -C 6烷基或C 2 -C 6烯基; T和U各自独立地表示氮原子或机组; V表示氧原子或硫原子。 本发明的化合物可用作各种ACC相关疾病的治疗剂。

    Substituted spirochromanone derivatives
    9.
    发明申请
    Substituted spirochromanone derivatives 有权

    公开(公告)号：US20080171761A1

    公开(公告)日：2008-07-17

    申请号：US12007000

    申请日：2008-01-08

    申请人： Tomoharu Iino ,  Hideki Jona ,  Jun Shibata ,  Tadashi Shimamura ,  Takeru Yamakawa ,  Lihu Yang

    发明人： Tomoharu Iino ,  Hideki Jona ,  Jun Shibata ,  Tadashi Shimamura ,  Takeru Yamakawa ,  Lihu Yang

    IPC分类号： C07D491/107 ,  A61K31/438 ,  A61P3/00

    CPC分类号： C07D519/00 ,  C07D491/10

    摘要： The invention relates to a compound of a general formula (I): wherein Ar1 represents a group formed from an aromatic ring selected from a group consisting of indole, 1H-indazole, 2H-indazole, 1H-thieno[2,3-c]pyrazole, 1H-pyrazolo[3,4-b]pyridine, benzo[b]furan, benzimidazole, benzoxazole, 1,2-benzisoxazole and imidazo[1,2-a]pyridine; R1 and R2 each represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkoxy group, a cyclo-C3-C6 alkyloxy group, a C2-C7 alkanoyl group, a halo-C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, a halo-C2-C7 alkoxycarbonyl group, a cyclo-C3-C6 alkyloxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; an optionally-substituted C1-C6 alkyl, aryl or heterocyclic group; or a C1-C6 alkyl or C2-C6 alkenyl group having the aryl or heterocyclic group; R3 and R4 each represent a hydrogen atom, a halogen atom, a nitro group, a cyclo-C3-C6 alkyl group, a carbamoyl group optionally substituted with a C1-C6 alkyl or cyclo-C3-C6 alkyl group, or a group of —N(Re)Rf; an optionally-substituted C2-C7 alkanoyl, C1-C6 alkoxy, C2-C7 alkoxycarbonyl, cyclo-C3-C6 alkyloxycarbonyl, C1-C6 alkylsulfonyl, C1-C6 alkylthio, cyclo-C3-C6 alkyloxy, cyclo-C3-C6 alkyl-C1-C6 alkoxy, cyclo-C3-C6 alkylsulfonyl, cyclo-C3-C6 alkylthio or cyclo-C3-C6 alkyl-C1-C6 alkylthio group; or an optionally-substituted C1-C6 alkyl group; T and U each represent a nitrogen atom or a methine group; and V represents an oxygen atom or a sulfur atom.The compound of the invention is useful as therapeutical agents for various ACC-related diseases.